Study S002076

A Randomized Controlled Open Label Pilot Study Examining the Safety of a 16 Week Flexible Titration Regimen vs. Label-recommended 8-week Semaglutide Titration Regimen

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04447859
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: UNKNOWN
Enrollment: 100
Start: 2020-02-23
Primary completion: 2022-05-10
Lead sponsor: Tel-Aviv Sourasky Medical Center
Conditions: Diabetes type2
Interventions: DRUG:Semaglutide; OTHER:label recommended titration
Results posted: FALSE

Registered primary outcomes

Gastrointestinal adverse events (GI-AEs) [16 weeks - from visit one to visit seven (and in each visit alone)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.